Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive.
EP. 1: Dr. Gandara on Developments in HER2-Targeted Therapies in NSCLC
David R. Gandara, MD, discusses recent developments in HER2-targeted therapies as a treatment for patients with non-small cell lung cancer.
EP. 2: Dr. Gainor on the Potential Value of Targeting TROP-2 and CEACAM5 in Lung Cancer
Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.
EP. 3: Dr. Santos on the Potential Role for CEACAM5- and KEAP1-Targeted Therapies in NSCLC
Edgardo S. Santos, MD, discusses the potential role for CEACAM5- and KEAP1-targeted therapies in non–small cell lung cancer.
EP. 4: Dr. Schenk on the Importance of Investigating Novel Targets in Lung Cancer
Erin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.
EP. 5: Dr. Skoulidis on the Rationale to Target TROP2 in Lung Cancer
Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the rationale to target TROP-2 in lung cancer.
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis
Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma
Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD
2 Clarke Drive Cranbury, NJ 08512